Abstract: Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with
advanced EGFR mutation-positive NSCLC. Methods Fifty patients with untreated advanced EGFR mutation- positive NSCLC
were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). The progression-free survival, objective
response rate and disease control rate were evaluated to compare the efficacy of gefitinib and erlotinib. Results There were no
significant differences in the objective response rate (P=0.711) and disease control rate (P=0.861) between the two groups. The
progression-free survival of gefitinib group and erlotinib group was 8.0 months and 10.0 months, respectively. The efficacy of
the two drugs was similar (P=0.293). Conclusion There is no significant differences between gefitinib and erlotinib in the
first-line treatment of patients with advanced EGFR mutation-positive NSCLC.